Pay in 4 interest-free payments of $5.25 Learn more
Ships within 48 hours · Estimated delivery Nov 2 - Nov 7
The FDA cleared orforglipron for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity, based on the ATTAIN clinical program which showed placebo-adjusted weight loss of 7.5% to 11.2% in non-diabetics (ATTAIN-1) and 5.1% to 9.6% in diabetics at different doses, along with the expected glycaemic benefits (ATTAIN-2)
Batch traceability shown up front Review the batch reference, linked COA when available, or contact support before placing an order
Zepbound Zepbound is a once-weekly injected medication that contains the same active ingredient as Mounjaro, tirzepatide
In cases where these outcomes were reported, in nearly all cases they were included as secondary outcomes and the studies often lacked sufficient power to reliably detect an effect
